Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Topics

next-generation sequencing · Precision medicine · Advanced cancer · tumour NGS · ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) · ESMO Precision Medicine Working Group · clinical actionability · Molecular target · treatment decision-making · cost-effectiveness · accessibility · Non-small cell lung cancer · prostate cancer · Colorectal cancer · cholangiocarcinoma · ovarian cancer · breast cancer · gastrointestinal stromal tumours · sarcoma · thyroid cancer · cancer of unknown primary · rare tumours · Metastasis · tumour-agnostic alterations · tumour-agnostic therapies · matched therapies · clinical research centres · routine clinical practice · Genomic profiling · molecular profiling · biomarker-driven therapy · Precision medicine · Somatic mutations · Genomic alterations